We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+17.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.99B
AUM Growth
+$232M
Cap. Flow
+$89.4M
Cap. Flow %
4.5%
Top 10 Hldgs %
47.8%
Holding
194
New
23
Increased
33
Reduced
38
Closed
65

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$46.6M
2
PBYI icon
Puma Biotechnology
PBYI
+$41M
3
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$35.9M
4
CORI
Corium International, Inc.
CORI
+$19M
5
ISRG icon
Intuitive Surgical
ISRG
+$17.9M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$37.6M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$22.2M
3
NVRO
NEVRO CORP.
NVRO
+$20.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.3M
5
AMAG
AMAG Pharmaceuticals
AMAG
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.26%
2 Consumer Staples 0.19%
3 Consumer Discretionary 0.06%
4 Energy 0.04%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABEO icon
76
Abeona Therapeutics
ABEO
$345M
$2.71M 0.14%
16,915
-8,000
-32% -$1.09M
OCRX
77
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.37M 0.12%
2,038,880
-111,120
-5% -$129K
VRNA
78
DELISTED
Verona Pharma
VRNA
$2.33M 0.12%
+200,000
New +$2.65M
XENE icon
79
Xenon Pharmaceuticals
XENE
$5.96B
$2.28M 0.11%
723,853
– –
MGCD
80
DELISTED
MGC Diagnostics Corporation
MGCD
$2.14M 0.11%
252,327
-50,000
-17% -$411K
BLUE
81
DELISTED
bluebird bio
BLUE
$2.1M 0.11%
1,544
+1,185
+330% +$1.43M
DMK
82
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$2.08M 0.1%
+5,714
New +$1.71M
EYPT icon
83
EyePoint Inc
EYPT
$431M
$1.97M 0.1%
114,956
-113,015
-50% -$2.15M
CRIS icon
84
Curis
CRIS
$3.76M
$1.8M 0.09%
476
+226
+90% +$944K
BCLI
85
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.66M 0.08%
+26,667
New +$1.64M
ADYX
86
DELISTED
Adynxx Inc
ADYX
$1.57M 0.08%
70,566
– –
TVRD
87
CALL
Tvardi Therapeutics
TVRD
$24.1M
$1.54M 0.08%
+2,778
New +$1.76M
ARWR icon
88
Arrowhead Research
ARWR
$12.6B
$1.37M 0.07%
847,458
– –
AFMD
89
DELISTED
Affimed
AFMD
$1.37M 0.07%
66,821
-6,609
-9% -$147K
EIGR
90
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.25M 0.06%
5,256
– –
EXEL icon
91
Exelixis
EXEL
$14B
$1.14M 0.06%
46,361
– –
LNTH icon
92
Lantheus
LNTH
$6.59B
$949K 0.05%
53,763
– –
OSUR icon
93
OraSure Technologies
OSUR
$257M
$945K 0.05%
54,729
+7,604
+16% +$109K
CSBR icon
94
Champions Oncology
CSBR
$68.6M
$943K 0.05%
366,973
+1
+0% +$3
GRDX
95
GridAI Technologies Corp
GRDX
$28.3M
$916K 0.05%
2
– –
WCG
96
DELISTED
Wellcare Health Plans, Inc.
WCG
$908K 0.05%
5,056
-227
-4% -$37.6K
OTLK icon
97
Outlook Therapeutics
OTLK
$157M
$837K 0.04%
5,237
-2,150
-29% -$607K
HSKA
98
DELISTED
Heska Corp
HSKA
$745K 0.04%
7,300
+1,000
+16% +$98.7K
OXFD
99
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$741K 0.04%
+44,106
New +$659K
LHCG
100
DELISTED
LHC Group LLC
LHCG
$728K 0.04%
10,730
+5,985
+126% +$357K
2 3
4
5 6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Perceptive Advisors held 194 positions worth $1.99B, up 13% from $1.76B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $89.4M of net new capital in Q2 2017, opening 23 new positions and adding to 33 existing holdings. Its largest new stake was Puma Biotechnology: 733,320 shares worth $64.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $22.2M trimmed.

  • Perceptive Advisors's largest Q2 2017 buy was Puma Biotechnology: 733,320 shares worth $64.1M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2017, an estimated $46.6M increase.
  • Perceptive Advisors's biggest Q2 2017 reduction was Sarepta Therapeutics, cutting an estimated $22.2M.
  • Perceptive Advisors fully exited Aclaris Therapeutics in Q2 2017, selling an estimated $37.6M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.99B portfolio in Q2 2017.
  • Perceptive Advisors opened 23 new positions and closed 65 in Q2 2017.
  • Perceptive Advisors's portfolio value rose 13% quarter-over-quarter to $1.99B.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.